RTIL 13
RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[1][2].
Product Specifications
CAS Number
1009376-10-6
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/rtil-13.html
Solubility
10 mM in DMSO
Smiles
O=C1[C@@]2([H])[C@](C(N1CC[N+](C)(C)CCCCCCCCCCCCCCCCCC)=O)([H])[C@H]3O[C@@H]2CC3.[Br-]
Molecular Formula
C30H55BrN2O3
Molecular Weight
571.67
References & Citations
[1]Zhang J, et, al. From Spanish fly to room-temperature ionic liquids (RTILs) : synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New Journal of Chemistry. 2008 Jan; 32 (1) : 1-180.|[2]Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of Newcastle. Tuesday, December 28, 2021.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
039800 200 µL
PDE1B, CT (PDE1B, PDE1B1, PDES1B, Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B, 63kD Cam-PDE)
Sign In for Pricing
View Details 